Drug Profile
Research programme: epigallocatechin gallate-based anticancer therapeutics - Viteava Pharmaceuticals
Alternative Names: EGCG-based anticancer therapeutics - Viteava; Green tea flavonoid-based anticancer therapeutics - Viteava; Proteasome endopeptidase complex inhibtors - Viteava; VEA-005; VEA-006; VPE-001; VPEA-002; VPEA-004Latest Information Update: 26 Apr 2023
Price :
$50
*
At a glance
- Originator H. Lee Moffitt Cancer Center and Research Institute; Hong Kong Polytechnic University; McGill University; University of South Florida; Wayne State University
- Developer McGill University; Viteava Pharmaceuticals
- Class Antineoplastics; Catechins; Flavonoids; Small molecules
- Mechanism of Action AMP activated protein kinase stimulants; Proteasome inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Cancer
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 27 Mar 2023 Discontinued - Preclinical for Cancer in Canada (unspecified route)
- 28 Jan 2021 No recent reports of development identified for preclinical development in Cancer in Canada
- 24 Jan 2019 VPE 001 is still in Preclinical phase for Cancer in Canada (Viteava Pharmaceuticals pipeline, January 2019)